CLINICAL_TRIALS
trial_result
· 2011-03-01
Clinical Trial Update: Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer [Phase 2]
Summary
Phase II trial of dasatinib for androgen-deprived progressive prostate cancer has completed; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-03-01